Breast Cancer Research and Treatment

, Volume 111, Issue 2, pp 303–311

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

  • Mieke Kriege
  • Caroline Seynaeve
  • Hanne Meijers-Heijboer
  • J. Margriet Collee
  • Marian B. E. Menke-Pluymers
  • Carina C. M. Bartels
  • Madeleine M. A. Tilanus-Linthorst
  • Ans van den Ouweland
  • Bert van Geel
  • Cecile T. M. Brekelmans
  • Jan G. M. Klijn
Epidemiology

DOI: 10.1007/s10549-007-9781-7

Cite this article as:
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. et al. Breast Cancer Res Treat (2008) 111: 303. doi:10.1007/s10549-007-9781-7

Abstract

Background Data on distant disease-free interval (DDFI) and the localization of the first distant metastasis (DM) in BRCA1- and BRCA2-associated breast cancer (BC) patients are as yet scarcely available. Patients and methods We identified 57 BRCA1-associated and 31 BRCA2-associated BC patients, diagnosed between 1980 and 2001, and developing DM disease before 2004, July 1. DDFI, the site(s) of first DM and post-relapse survival of these patients were compared with those of 192 sporadic BC patients. Results As compared to sporadic patients, BRCA1 patients developed less often bone DM (30% vs. 51%; P = 0.005), but tended to develop more often lung DM (26% vs. 16%; P = 0.07), and DM at multiple sites (44% vs. 32%; P = 0.11). In BRCA2-associated compared to sporadic patients, first DM more commonly occurred in lymph nodes (23% vs. 7%; P = 0.007) and at multiple sites (48% vs. 32%; P = 0.08). Adjuvant systemic therapy appeared to be most effective in BRCA2 mutation carriers. Post-relapse survival was worse for BRCA1- and better for BRCA2-associated patients as compared to sporadic patients, but differences disappeared after adjustment for ER-status, site of first DM and DDFI. Conclusion The site of first DM is different between BRCA1- and BRCA2-associated and sporadic BC patients. Differences in post-relapse survival could be explained by differences in site of first DM, in ER-status and in DDFI. Treatment efficacy may differ dependent on genetic status.

Keywords

BRCA1BRCA2Breast cancerDistant disease-free intervalPost-relapse survivalSite of first relapse

Abbreviations

BC

Breast cancer

DDFI

Distant disease-free interval

DM

Distant metastasis

ER

Estrogen receptor

PgR

Progesterone receptor

Copyright information

© Springer Science+Business Media, LLC. 2007

Authors and Affiliations

  • Mieke Kriege
    • 1
  • Caroline Seynaeve
    • 1
  • Hanne Meijers-Heijboer
    • 2
    • 3
  • J. Margriet Collee
    • 2
  • Marian B. E. Menke-Pluymers
    • 4
  • Carina C. M. Bartels
    • 4
  • Madeleine M. A. Tilanus-Linthorst
    • 4
  • Ans van den Ouweland
    • 2
  • Bert van Geel
    • 4
  • Cecile T. M. Brekelmans
    • 1
  • Jan G. M. Klijn
    • 1
  1. 1.Department of Medical Oncology, Rotterdam Family Cancer ClinicErasmus MC-Daniel den Hoed Cancer CenterRotterdamThe Netherlands
  2. 2.Family Cancer Clinic, Department of Clinical GeneticsErasmus MC RotterdamThe Netherlands
  3. 3.Department of Clinical GeneticsVU Medical CenterAmsterdamThe Netherlands
  4. 4.Family Cancer Clinic, Department of SurgeryErasmus MC-Daniel den Hoed Cancer CenterRotterdamThe Netherlands